This program is funded by an independent grant from Pfizer Global Medical Grants. This online education program has been designed solely for healthcare professionals in Latin America, Africa, Asia-Pacific & the Middle East. The content is not available for healthcare professionals in United Kingdom, South Korea, Japan, China, New Zealand, Australia or any other country.

In this interactive education our global expert panel present cases and discuss new research, clinical trials, novel therapies and the latest global guidelines for the diagnosis and management of Duchenne Muscular Dystrophy with Q&A.

They will cover the early identification of DMD, including common and rare red flags and the available screening tools. They will explore referral paths and prioritisation of at-risk patients.

The education will also explore how geographic and demographic disparities can affect the diagnosis, management and care of patients with DMD and discuss strategies to mitigate these.

1.5 AMA PRA Category 1 Credits™ are available for this session.

This is the first of two sessions on Duchenne Muscular Dystrophy. You are welcome to join one of both sessions for free.

Learning Objectives

Implement Early Identification Techniques for DMD:

• Utilize validated screening tools to identify early clinical markers of DMD in at-risk pediatric populations.
• Apply a tiered approach to screening, starting with primary care assessments and escalating to specialized testing when red flags are present.

Utilize Multidisciplinary Referral Networks for Best Practice in DMD:

• Establish or integrate with existing referral networks that include pediatric neurologists, neuromuscular specialists, and geneticists for expedited diagnosis.
• Implement protocols for prioritizing high-risk cases for faster evaluations by specialists.

Address Geographic and Demographic Disparities in the Care of Patients with DMD:

• Identify systemic barriers, such as geographic distance or limited healthcare access, that delay DMD diagnosis in your practice or community.
• Develop and initiate targeted outreach programs or clinics aimed at overcoming these identified disparities.

Who is this course for

This online education program has been designed for healthcare professionals in Latin America, Africa, Asia-Pacific & the Middle East. The content is not available for healthcare professionals in United Kingdom, South Korea, Japan, China, New Zealand & Australia. The course provides continuing education for:

✅ Paediatricians

✅ Neurologists

✅ Family Physicians

✅ Physicians

✅ Physician Assistants

✅ Nurse Practitioners

✅ Other Health Professionals

Faculty:

Professor Alberto Dubrovsky

Alberto Dubrovsky is Professor of Neuroscience and Neurology at the University of Buenos Aires and Director of the Department of Neurology. He is President of the Latin American Society of Neuromuscular Diseases (SOLANE), Past President of the Argentine Neurological Society and a member of the Executive Committee-Research Group of Neuromuscular Diseases of the World Federation of Neurology. He belongs to CINRG (Cooperative International Neuromuscular Research Group), an organization dedicated to DMD research working with hundreds of patients, many of whom have been involved in the research since the early 1990s. He has a strong commitment to education in DMD and has given given a great number of lectures on this subject throughout Latin America.

Professor Rasha El Sherif

Professor El Sharif is a highly regarded doctor of Neurology & Genetic diagnosis of Neuromuscular disorders, with over 15 years specializing in the clinical diagnosis and management of muscular dystrophy. She is a WHO rare disorders Expert panel member, has served as the Director of the Neuromuscular Registry, is a member of the Rare Disease Committee at the Egypt Genome Project and is the Faculty Neurology Module Lead and an expert in rare disorders at NewGiza University School of Medicine. She is the founder of the MYO-CARE National Foundation and Director of the MYO-CARE Neuromuscular Centre and she chairs the Rare Disorders Subcommittee. She also directs the Neuromuscular & Neuro-genetics Unit at EgyptAir Hospital.

Emily Rueben OBE

Emily Rueben, co-founder and CEO of Duchenne UK, has made significant strides in the fight against Duchenne muscular dystrophy (DMD) since her eldest son's diagnosis. An Oxford history graduate and former journalist for Channel 4 News and CNN International, she founded Duchenne Children’s Trust, which later became Duchenne UK. Her advocacy has taken her to major regulatory agencies worldwide, earning recognition in the UK House of Commons and a Points of Light award from the UK Prime Minister. Emily has served on several healthcare advisory councils and was honored with an OBE for her contributions to charity and DMD in 2023.

Faculty, planners, and staff disclosure information

AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Alberto Dubrovsky is on advisory boards for PTC, Roche, Sarepta, Biogen, Novartis, Biomarin, Sanofi, Genzyme, Takeda and Ultragenyx. He has received speaking fees/honoraria from Biogen, Genzyme, Sanofi, Sarepta, PTC and Roche. He has received grants or research funding from Sanofi, Genzyme, PTC, Novartis and Biogen.

Emily Rueben & Rasha El Sherif have no relevant financial or non-financial interests to disclose.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Accreditation statements

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse Practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Other Health Professionals: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries

This continuing education activity is active starting 17 April 2024 and will expire on 17 April 2025. Estimated time to complete this activity: 1.5 hours. For all continuing education and content inquiries, including questions to speaker(s), please contact us at ce@affinityced.com

This program is funded by an independent grant from Pfizer Global Medical Grants.